FDA approves fusion protein for treatment of lymphoma.
Piascik
P
P
University of Kentucky College of Pharmacy, Lexington, USA.
D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000737:chemistry; D007376:Interleukin-2 / Q000737:chemistry; D008223:Lymphoma / Q000188:drug therapy*; D011506:Proteins / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D004167:Diphtheria Toxin; D007376:Interleukin-2; D011506:Proteins; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox